Document is current
Any future updates will be listed below
-
Authors
Zhang, Pengyue
Hou, Yuan https://orcid.org/0000-0002-3900-6122
Chiang, Chien-Wei
Pieper, Andrew A.
Cummings, Jeffrey
Cheng, Feixiong https://orcid.org/0000-0002-1736-2847
- License Information
-
More Information
Article History
Received: 29 May 2022
Accepted: 31 March 2023
First Online: 22 May 2023
Competing interests
: J.C. has provided consultation to Acadia, Actinogen Medical, Alkahest, Alzheon, Annovis Bio, Avanir Pharmaceuticals, Axsome Therapeutics, Biogen, BioXcel Therapeutics, Cassava Sciences, Cerecin, Cerevel Therapeutics, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight Pharmaceuticals, GemVax, Genentech, Green Valley, Grifols, Karuna Therapeutics, Merck, Novo Nordisk, Otsuka Pharmaceuticals, Resverlogix, Roche, Biosplice Therapeutics (formerly) Samumed, Samus Therapeutics, Signant Health, Suven Life Sciences, Third Rock Ventures and United Neuroscience. J.C. has stock options in Adamas Pharmaceuticals, Annovis Bio, MedAvante and Bioasis Technologies. The remaining authors declare no competing interests.
